Xention partners its lead atrial fibrillation drug with Servier

Xention and Servier announce a cardiovascular collaboration to further develop a selective Kv1.5 modulator for the treatment of atrial fibrillation.

Please see attached press release for the full announcement.

Xention Limited

Xention Limited
Atrial fibrillation drug development

Website
www.xention.com

Downloads

DownloadDownloads